Hirotaka Nagasaka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hirotaka Nagasaka has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Brian Shuch
UCLA School of Medicine 14 Institute of Urologic Oncology Los Angeles, California
15 shared publications - Christopher J. Ricketts
Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
15 shared publications - Daiki Ueno
Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
15 shared publications - Erika Muraoka
Department of Molecular Pathology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
15 shared publications - Go Noguchi
Department of Urology Yokohama City University Graduate School of Medicine Yokohama Kanagawa Japan
15 shared publications - Hidekazu Nishizawa
Department of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860-8556, Japan
15 shared publications
Latest Publications
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of ALK Fusion Gene-Associated Renal Tumorigenesis
Table S3. Count data of RNA-seq analysis.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of ALK Fusion Gene-Associated Renal Tumorigenesis
Table S3. Count data of RNA-seq analysis.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of ALK Fusion Gene-Associated Renal Tumorigenesis
Figure S1. Doxycycline has no effect on HKO differentiation.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of ALK Fusion Gene-Associated Renal Tumorigenesis
Figure S1. Doxycycline has no effect on HKO differentiation.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of ALK Fusion Gene-Associated Renal Tumorigenesis
Table S1. Marker genes used for clustering cell subtypes.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of ALK Fusion Gene-Associated Renal Tumorigenesis
Table S1. Marker genes used for clustering cell subtypes.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Data from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of ALK Fusion Gene-Associated Renal Tumorigenesis
Although kidney cancer arises from a variety of nephron cells with diverse characteristics and develops intratumor heterogeneity, a model to elucidate these complexities is incompletely developed. In this study, we report a genetically engineered human induced pluripotent stem cell–derived kidney organoid (HKO) model, which may recapitulate an early stage of renal tumorigenesis. When we overexpressed the VCL-ALK fusion gene, a renal oncogene, in HKO, tubular cells proliferated, and this proliferation was sustained under long-term culture or hypoxic conditions. In addition, the proliferating tubular cells migrated into the renal parenchyma of host mice upon transplantation. The deconvolution analysis and IHC revealed that the proliferating tubular cells could be arrested at an immature tubular progenitor stage with increased expressions of LIM homeobox protein 1 and jagged canonical Notch ligand 1, critical regulators of nephrogenesis. Our HKO model advances our understanding of renal tumorigenesis in the context of the trajectory of nephron development.Implications:Dysregulated nephron developmental machinery leads to aberrant cell proliferation of immature renal tubules.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of ALK Fusion Gene-Associated Renal Tumorigenesis
Although kidney cancer arises from a variety of nephron cells with diverse characteristics and develops intratumor heterogeneity, a model to elucidate these complexities is incompletely developed. In this study, we report a genetically engineered human induced pluripotent stem cell–derived kidney organoid (HKO) model, which may recapitulate an early stage of renal tumorigenesis. When we overexpressed the VCL-ALK fusion gene, a renal oncogene, in HKO, tubular cells proliferated, and this proliferation was sustained under long-term culture or hypoxic conditions. In addition, the proliferating tubular cells migrated into the renal parenchyma of host mice upon transplantation. The deconvolution analysis and IHC revealed that the proliferating tubular cells could be arrested at an immature tubular progenitor stage with increased expressions of LIM homeobox protein 1 and jagged canonical Notch ligand 1, critical regulators of nephrogenesis. Our HKO model advances our understanding of renal tumorigenesis in the context of the trajectory of nephron development.Implications:Dysregulated nephron developmental machinery leads to aberrant cell proliferation of immature renal tubules.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of ALK Fusion Gene-Associated Renal Tumorigenesis
Table S3. Count data of RNA-seq analysis.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of ALK Fusion Gene-Associated Renal Tumorigenesis
Table S3. Count data of RNA-seq analysis.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of ALK Fusion Gene-Associated Renal Tumorigenesis
Figure S3. VCL-ALK overexpressing HKO derived from HPS0381, another human iPSCs, exhibits proliferating tubular cells.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of ALK Fusion Gene-Associated Renal Tumorigenesis
Figure S3. VCL-ALK overexpressing HKO derived from HPS0381, another human iPSCs, exhibits proliferating tubular cells.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of ALK Fusion Gene-Associated Renal Tumorigenesis
Figure S4. VCL-ALK fusion gene might drive proliferation of tubular cells in an early stage of nephrogenesis.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of ALK Fusion Gene-Associated Renal Tumorigenesis
Figure S4. VCL-ALK fusion gene might drive proliferation of tubular cells in an early stage of nephrogenesis.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of ALK Fusion Gene-Associated Renal Tumorigenesis
Figure S6. Immature tubular progenitor cells might proliferate in VCL-ALK overexpressing HKO.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of ALK Fusion Gene-Associated Renal Tumorigenesis
Figure S6. Immature tubular progenitor cells might proliferate in VCL-ALK overexpressing HKO.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of ALK Fusion Gene-Associated Renal Tumorigenesis
Table S1. Marker genes used for clustering cell subtypes.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of ALK Fusion Gene-Associated Renal Tumorigenesis
Table S1. Marker genes used for clustering cell subtypes.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of ALK Fusion Gene-Associated Renal Tumorigenesis
Figure S6. Immature tubular progenitor cells might proliferate in VCL-ALK overexpressing HKO.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Genetically Engineered Human iPS Cell-Derived Kidney Organoid Recapitulates an Early Stage of ALK Fusion Gene-Associated Renal Tumorigenesis
Figure S6. Immature tubular progenitor cells might proliferate in VCL-ALK overexpressing HKO.